Imunofan® (Imunofan®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceArginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginineArginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine
Similar drugsTo uncover
  • Imunofan®
    spray nazal. 
    BIONOKS NPP, LLC     Russia
  • Imunofan®
    solution w / m PC 
    BIONOKS NPP, LLC     Russia
  • Imunofan®
    suppositories rect. 
    BIONOKS NPP, LLC     Russia
    • Dosage form: & nbspsolution for intramuscular and subcutaneous administration
    Composition:

    Aactive substance: imunofan 0.005 g, Excipients (glycine 0.5 g, sodium chloride 0.9 g, water for injection up to 100 ml).

    Description:Colorless transparent liquid.
    Pharmacotherapeutic group:Immunomodulating agent
    ATX: & nbsp

    L.03.A.X   Other immunostimulants

    Pharmacodynamics:

    The drug has an immunoregulatory, detoxification, hepatoprotective action and causes inactivation free radical and peroxide compounds. The pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the oxidative-antioxidant reaction of the organism and inhibition of multiple drug resistance mediated by proteins of the transmembrane transport pump of the cell.

    Pharmacokinetics:

    The action of the drug begins to develop within 2-3 hours after administration (rapid phase) and lasts up to 4 months (medium and slow phases).

    During the fast phase (beginning in 2-3 hours, duration - up to 2-3 days), detoxification effect manifests itself first: the antioxidant defense of the body is enhanced by stimulation of the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes the level of lipid peroxidation, inhibits the disintegration of phospholipids of the cell membrane and the synthesis of arachidonic acid, followed by a decrease in the concentration of cholesterol in the blood and the production of inflammatory mediators. With toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the concentration of bilirubin in the blood serum.

    During the middle phase (beginning 2-3 days, duration - up to 7-10 days), there is an intensification of the reactions of phagocytosis and death of intracellular bacteria and viruses.

    During the slow phase (beginning on the 7th-10th day, duration of up to 4 months), immunoregulatory action of Imunofan manifests itself - restoration of the disturbed parameters of cellular and humoral immunity. During this period, the normalization of the immunoregulatory index is observed, an increase in the production of specific antibodies is noted.The influence of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the action of certain therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reactive antibodies of the class IgE (immunoglobulin E) and does not enhance the hypersensitivity reaction immediate type. The drug stimulates the formation of IgA (immunoglobulin A) with its congenital insufficiency.

    Imunofan effectively suppresses the multiple drug resistance of tumor cells and increases their sensitivity to the action of cytotoxic drugs.

    Indications:

    In adults as an adjuvant for vaccination against bacterial and viral infections.

    Prevention exacerbation of chronic infectious-inflammatory diseases of various etiology, taking place against the background of immunodeficiency in adults and children over 2 years: chronic viral hepatitis, brucellosis.

    Prevention development of toxicosis the children older than 2 years from malignant diseases of the hematopoietic and lymphoid tissue on the background of the course of chemoradiotherapy.

    Treatment in the complex therapy of secondary immunodeficiency and toxic conditions caused by the following diseases.

    In adults:

    - in the complex therapy of oncological diseases in the scheme of radical combined treatment (chemoradiotherapy and surgery), in complex or symptomatic therapy in patients with a widespread tumor process (III-IV stage) of different localization;

    - in the complex therapy of chronic viral hepatitis, chronic brucellosis;

    - in the complex therapy of HIV infection, opportunistic infections (cytomegalovirus, herpetic infections, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis);

    - in the treatment of burns III-IV degree with the phenomena of toxemia, septicotoxemia, in surgical patients with septic endocarditis, cholecystopancreatitis, long-term non-healing wounds of the extremities, purulent-septic complications;

    - in the complex therapy of bronchial obstructive syndrome, rheumatoid arthritis, psoriasis.

    In adults and children older than 2 years:

    - in the complex therapy of inflammatory eye diseases;

    - in the treatment of diphtheria, diphtheria bacteriocarrier.

    In children older than 2 years:

    - in the complex therapy of larynx and pharyngeal papillomatosis.

    Contraindications:

    Hypersensitivity to the components of the drug. Children up to 2 years.

    Pregnancy and lactation:

    Because of insufficient knowledge in pregnancy and during breastfeeding is used only if the intended benefit for the mother exceeds the potential risk to the fetus and the baby.

    Dosing and Administration:

    Imunofan is administered subcutaneously or intramuscularly in a single dose of 50 μg. The maximum daily dose is 50 mcg. The drug is used in courses, depending on the purpose and nature of the disease.

    In adults.

    As an adjuvant when vaccinated against bacterial and viral infections - once in a dose of 50 mcg intramuscularly or subcutaneously on the day of vaccination.

    In the complex treatment of cancer patients:

    - in the scheme of radical combined treatment - once a day, a course of 8-10 injections before chemoradiotherapy and surgery followed by continuation of the course throughout the treatment period.

    - in patients with a common tumor process - once a day, a course of 8-10 injections,with a break of 15-20 days and a repetition of the course during the entire subsequent treatment period.

    In the complex treatment of patients with chronic viral hepatitis and brucellosis:

    - once a day, a course of treatment of 15-20 injections.

    In the complex therapy of HIV infection and opportunistic infections:

    once a day, a course of treatment of 15-20 injections. If necessary, it is possible to hold a second course in 2-4 weeks.

    In surgical patients, in the treatment of burns III-IV degree with the phenomena of toxemia, septicotoxemia, in surgical patients with septic endocarditis, cholecystopancreatitis, long-lasting non-healing wounds of the extremities, purulent-septic complications:

    - once a day, the course of treatment 7-10 injections, if necessary, the course of the drug can be extended to 20 injections.

    With bronchoobstructive syndrome, rheumatoid arthritis:

    - once in 3 days, the course of treatment 8-10 injections, if necessary, the course of treatment can be extended to 20 injections.

    In the complex therapy of psoriasis:

    - once a day, a course of treatment of 15-20 injections.

    In adults and children older than 2 years.

    In the complex therapy of inflammatory eye diseases:

    - with lesions of the anterior parts of the eye (keratitis, keratouveitis) daily once, treatment 7-10 injections;

    - with lesions of mainly the posterior parts of the eye (peripheral, posterior uveitis, retinovasculitis) and generalized inflammatory processes once a day, the course of treatment is 15-20 injections.

    In the treatment of diphtheria:

    - once a day, treatment course 8-10 injections. When diphtheria bacteriocarrier - once in 3 days, on the course - 3-5 injections.

    In the complex therapy of children with papillomatosis of the larynx and oropharynx in children older than 2 years:

    - once a day, the course of treatment - 10 injections.

    For prevention:

    exacerbation of chronic viral hepatitis and chronic brucellosis in adults and children over 2 years of age

    once a day with 15-20 injections, repeated preventive courses are recommended every 2-3 months;

    development of toxicosis in children older than 2 years with malignant diseases of the hematopoietic and lymphoid tissue

    - once a day, the course of treatment 10-20 injections, during and after the end of the course of chemoradiotherapy.

    Side effects:

    Individual intolerance is possible. Allergic reactions are possible reaction.

    Overdose:

    Cases of drug overdose are not known.

    Interaction:

    In clinical practice cases of interaction of Imunofan with other medicinal preparations have not been registered.

    The effect of the drug does not depend on the production of prostaglandin E2, in this connection, the appointment of Imunofan is possible in combination with anti-inflammatory steroidal and nonsteroidal drugs.

    Special instructions:

    As a result of the activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

    Effect on the ability to drive transp. cf. and fur:

    The drug does not affect the ability to drive vehicles, mechanisms.

    Form release / dosage:

    Solution for intramuscular and subcutaneous administration.

    Packaging:Ampoules containing 50 μg of the drug in 1.0 ml of the solution. 5 ampoules with the instruction are placed in a pack of cardboard, or 5 ampoules are put into the contour cell package, 1 circuit cell pack with the instruction is placed in a cardboard pack.
    Storage conditions:

    In the dark place at a temperature of 2 ° C to 10 ° C. Keep out of the reach of children.

    Shelf life:

    3 years.Do not use the product after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N000106 / 02
    Date of registration:18.08.2010 / 03.12.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:BIONOKS NPP, LLC BIONOKS NPP, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp06.11.2017
    Illustrated instructions
      Instructions
      Up